Myocarditis following rAd26 and rAd5 vector-based COVID-19 vaccine: case report
Related Experiment Video
Updated: Aug 8, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Farah Naghashzadeh1, Shadi Shafaghi1, Atosa Dorudinia2
1Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
SARS-CoV-2 vaccines provide a safe solution with a major impact on reducing the spread of the virus and mild side effects. Research has shown rare cases of myocarditis after mRNA vaccines. This study presents a 29-year-old male with chest pain after 48 h of receiving rAd26 and rAd5 vector-based COVID-19 vaccine (Sputnik V vaccine). The electrocardiogram revealed ST-segment elevation. Also, the laboratory screening was remarkable for elevated cardiac Troponin-I level, and leukocytosis; and echocardiography depicted severe left ventricular systolic dysfunction. Overall, endomyocardial biopsy proved lymphocytic myocarditis such that the patient was successfully treated with immunosuppressive and guideline-directed medical treatment.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management

